The SEA Lab, a program, of the Los Angeles Conservation Corps Celebrates 20 Years of Serving the South Bay.

Beloved local aquarium rescues marine life and teaches children.

REDONDO BEACH, CA, USA, September 21, 2017 /EINPresswire.com/ —
—— The SEA Lab, a program of the LA Conservation Corps celebrates 20 years of operations this month. With a unique relationship with local power plants as well as the government organization, the Department of Fish and Wildlife, the organization has rescued and rehabilitated thousands of marine animals and used them to educate local students from various schools in the area.

Based on the border of Hermosa and Redondo Beach, the beloved local attraction has rescued thousands of marine animals in a wide array of species including: sea horses, moon jellies, octopus, halibut, sharks, sea bass and many more.

The SEA Lab Director, Maria Madrigal was one of the first people hired at the aquarium and has served in numerous roles before her most recent appointment states: “It’s been wonderful to observe the transformation from a rustic, bare-bones structure to the facility it is today. I’ve observed children I taught in grade school and watched them grow into our high school volunteers and some have become corpsmembers. I’ve witnessed injured marine life get rescued and recover to thriving animals.”

Occupying and rehabbing a once faded building has been a 20-year transformation with SEA Lab picking up multiple beautification awards. The once barely-noticed aquarium now greets nearly 20,000 students and families each year and has become a local tourist attraction for beach-goers and tourists.

About the LA Conservation Corps
The LA Conservation Corps is an environmentally-focused youth development organization. We transform the lives of youth from disadvantaged communities through work and education. Work projects improve the quality of life for our communities and protect the environment for future generations.

Website:
www.lacorps.org

Socials:
https://www.facebook.com/LACorps
https://www.facebook.com/The.SEA.Lab.LACorps/
For more information, contact: Mike Mena at: 310-316-0612 or mike@ileanainternational.com
 
# # #

Mike Mena
Los Angeles Conservation Corps
310-913-0625
email us here


Source: EIN Presswire

Study Shows Gastric Bypass Surgery Effective for Long-Term Weight Loss and Prevention of Diabetes and Hypertension

Twelve year study shows effectiveness of gastric bypass surgery

SALT LAKE CITY, UTAH, USA, September 21, 2017 /EINPresswire.com/ — The findings from a 12-year study following individuals who received gastric bypass surgery were published recently in the New England Journal of Medicine, which demonstrated the long-term durability of weight loss following gastric bypass surgery. The percentage of weight loss/gain among the gastric bypass group changed very little from six to 12 years. The results also showed gastric bypass surgery effective in the long-term remission of diabetes and in preventing the occurrence of diabetes, as well as hypertension and dyslipidemia.

Funded by the National Institute of Diabetes and Digestive Kidney Diseases at the National Institute of Health (NIDDK/NIH), the study was a joint effort by Intermountain Healthcare, University of Utah School of Medicine, St. Mark’s Hospital, and Rocky Mountain Associated Physicians in Salt Lake City.

In total, 1,156 subjects consisting of patients who initially had gastric bypass surgery and two, severely obese non-surgical comparison groups, participated in the study. Clinical examinations occurred at baseline, two, six and 12 years. While body weight had very little change over 12 years in the non-surgery comparison groups, the gastric bypass group lost 35 percent of their initial weight at two years, 28 percent at six years and 27 percent at 12 years. For gastric bypass patients who had diabetes prior to their weight loss surgery, 75 percent of these patients had a remission of their diabetes at two years follow-up, and at 12 years, 51% of these patients were still in remission. The risk of becoming diabetic was 92% less among the participants who had had gastric bypass surgery when compared to the non-surgery participants. Similar favorable findings were found in the gastric bypass surgery group compared to the non-surgery participants with regards to high blood pressure and high cholesterol.

“The results of this study demonstrated the long-term durability of weight loss following gastric bypass surgery,” said Ted Adams, PhD, study lead and Intermountain Healthcare researcher. “The percentage of weight loss among the gastric bypass groups changed very little from six to 12 years. The results also show gastric bypass surgery is effective in the long-term remission of diabetes and is very effective in preventing the occurrence of diabetes.”

“Based upon the findings of this study, gastric bypass appears to be effective for significant, long-term weight loss and for the treatment and prevention of diabetes. The decision to have gastric bypass surgery should include individual assessment of risks and benefits of the surgery and consultation with one’s healthcare provider,” said Adams.

“One of the biggest benefits of gastric bypass surgery, beyond long-term weight loss, was the impact on diabetes,” said Paul Hopkins, MD, professor of Internal Medicine at the University of Utah Health. “If a patient received the surgery early in the course of diabetes, either before they were taking medication or before they began treating the disease with insulin injections, we found that 73 percent of patients remained in remission from diabetes.”

“This prospective study is remarkable because of its exceptional degree of follow-up and comprehensive evaluation of the long-term effects of gastric bypass surgery on both weight and metabolism,” said Rod McKinlay, MD, St. Mark’s Hospital. “ In addition to showing durable weight loss and significant improvement in type 2 diabetes, high blood pressure, and cholesterol levels, the study also demonstrated long-term improvements in physical functioning and quality of life for gastric bypass patients.”

Steven Simper, MD, St. Mark’s Hospital, added “This study strongly reinforces the recent position statements from the International Diabetes Federation and American Diabetes Association recommending bariatric surgery for patients with obesity and type 2 diabetes. We encourage patients to thoughtfully consider surgery earlier rather than later as part of a comprehensive treatment approach for type 2 diabetes.”

Lance Madigan
Intermountain Healthcare
(801) 442-3217
email us here


Source: EIN Presswire

Think Silicon Partners with Synopsys for Groundbreaking Ultra-Low Power IoT Platform for Wearables

IoT Platform Graphics Subsystem

Unveiling planned for Synopsys ARC Processor Summit and Linley Processor Conference 2017

By developing an IoT platform that combines ARC EM5D Processor IP and NEMA micro-GPU IP, we help our mutual customers to more rapidly implement high-quality 2D/3D graphics with reduced risk and cost.”

— John Koeter, Vice President of Marketing for IP at Synopsys

TORONTO, ONATRIO, CANADA, September 21, 2017 /EINPresswire.com/ — Think Silicon, a leader in developing ultra-low power graphics IP technology, has partnered with Synopsys to a create a prototype of an ultra-low power Internet of Things (IoT) platform designed for connected wearable, mobile, and embedded display devices. Think Silicon will unveil the solution at the ARC® Processor Summit 2017, September 26, 2017, at the Santa Clara Marriott, Santa Clara, California, and at the Linley Processor Conference, October 4-5, 2017 at the Hyatt Regency, Santa Clara, California.

The prototype combines the best of Synopsys technology sporting a DesignWare® ARC EM5D Processor with Think Silicon products including NEMA|p, NEMA|DC, and NEMA|GFX-API, resulting in a developer solution aimed at ultra-low power connected wearables and low-power embedded applications. Both companies have tools to assist developers in creating world-class products for a wide variety of markets.
Iakovos Stamoulis, CTO at Think Silicon, will present “Ultra-low Power 3D Micro-GPU for IoT-Class Devices” at the Synopsys ARC Processor Summit on September 26th and at the Linley Processor Conference on October 4. He will address how the emerging IoT market adds design challenges for engineers while discussing how the NEMA Series of ultra-low power micro-GPU cores bridges this gap.

“An increasing number of wearables and other IoT devices are being deployed with displays, requiring designers to find processing solutions with the best balance between graphics performance and power consumption,” said John Koeter, Vice President of Marketing for IP at Synopsys. “By developing an IoT platform that combines Synopsys’ low-power ARC EM5D Processor IP and Think Silicon’s NEMA Series of micro-GPU cores, we help our mutual customers to more rapidly implement high-quality 2D/3D graphics in their connected devices with reduced risk and cost.”

“Think Silicon is proud to partner with Synopsys to create this groundbreaking IoT platform prototype,” said Ulli Mueller, Vice President, Marketing & Business Development of Think Silicon. “We joined forces to build a development platform for graphically rich display applications based on minimal hardware power support. We’re excited to showcase this IoT platform prototype to attendees at both the prestigious Linley Processor Conference and the ARC Processor Summit. These are two unique opportunities to share this new partnership with potential customers and developers with a goal of inspiring developers to create great wearable solutions.”
NEMA|dc contains several smart tools and functions to compose multiple graphics and video layers by improving image quality and helping to reduce the system-on-a-chip (SoC) power consumption. These are backed with support for powerful composition features, a wide range of display interfaces, and advanced proprietary frame-buffer compression technology (TSFBc).

NEMA|p is the smallest member of the NEMA-GPU series and has been specifically designed to serve the need to build economically smart SoCs that drive small yet vibrant display applications.

The NEMA|GFX-API (Application Programming Interface) is designed to accelerate high-quality Graphics User Interface (GUI) development for embedded and wearable devices. The key differentiation from other API offerings is support for ultra-low power functions without the overhead of unnecessary programming instructions for IoT hardware.
For more information about Think Silicon, please visit think-silicon.com

About Think Silicon:
Think Silicon S.A. is a privately held Limited Company founded in 2007, located in Patras, Greece (HQ), Toronto, Canada (Business Development & Marketing office), and San Jose, CA, USA (Sales office). Think Silicon is specialized in developing and licensing high-performance graphics IP technology for ultra-low power and area-limited digital devices for worldwide semiconductor technology customers.

Contact:
PRESS Think Silicon +1 647.824.2006 info(at)think-silicon.com

Ulli Mueller
Think Silicon S.A.
+1 647 824 2006
email us here


Source: EIN Presswire

Agenda released for the highly anticipated 7th Pharmaceutical Microbiology event: Join, Pfizer, GSK, Sanofi and more

SMi proudly presents the return of the 7th annual Pharmaceutical Microbiology conference to Holiday Inn Kensington Forum, London on 22 – 23 January 2018

LONDOM, UNITED KINGDOM, September 21, 2017 /EINPresswire.com/ — The microbiology market has significantly grown in recent years as the demand from end user industries increases. Recent years have seen extraordinary advances in the technologies available to study microbial biology. The development of new techniques to probe individual cells and molecules is a major driver of scientific advance. This topic will be addressed throughout the 'Sterility Assurance and Rapid Microbial Methods' section of day two. The presentations will aim to cover and showcase several new advanced techniques that have been successfully applied to microbiology and have diverse applications which we know will attract a broad audience across all disciplines.

The 2018 meeting of minds will once again provide the perfect forum to discuss new advancements and showcase the latest innovations to keep you at the forefront of a dynamic and rapidly evolving market and will include presentations from both regulatory and industry experts sharing recent case studies and developing trends in the field of pharmaceutical microbiology.

The 2018 agenda will focus on the complex challenge that the field is facing such as endotoxin testing, best practices in cleaning & disinfection, contamination control case studies and rapid microbial-detection methods.

To find out more about the event please visit: www.pharma-microbiology.com/EIN

2018 Expert speaker line-up:
• Patrick Nieuwenhuizen, Manager Quality Control, Genzyme Ireland Ltd
• Ingo Spreitzer, Deputy head, Section Microbial safety, Paul Ehrlich Institut
• Francesco Boschi, Site Quality Assurance Manager, Pfizer
• Benoit Ramond, Senior Microbiology Expert, Sanofi
• Felix Montero Julian, Scientific Director, BioMérieux
• Shahram Lavasani, CEO, ImmuneBiotech AB
• Ian Symonds, Head, Aseptic Intelligence and Strategy, GSK
• Jeremy Webb, Professor of Microbiology, Principal Investigator Biofilms and Microbial Communities University Of Southampton
• Renate Rosengarten, Professor and Chair of Bacteriology and Hygiene, University of Veterinary Medicine Vienna
• Ruth Daniels, Senior Scientist, Microbiology Expert, Janssen Pharmaceuticals
• Jan-Oliver Karo, Assessor, Paul Ehrlich Institut
New Topics of discussion will include:
• How the development of mycoplasma testing could potentially revolutionise quality control
• Fungal and bacterial spores and spore contamination control
• Mycoplasma control and safety concepts in the 21st century – A regulator's view on ATMPs
• Bio contamination control – is it time to change our approach?
• General sterility and aseptic technique
• Environmental monitoring – managing excursions and out of trends
• Biofilms – what are they and why do they pose such an issue within drug development and delivery

The event will also feature two post-conference workshops, Addressing Objectionable Organisms – What, Why, Who, How? and Rapid Microbial Methods (Led by Sanofi and Battellle Memorial Institute).

Join the room full of industry experts to discuss: microbial contamination in aseptic manufacturing environments; risk assessments in fungal spore and bacterial spore excursions; optimising rapid microbial detection methods; tackling the current challenge of biofilms and much more.

2018 Sponsors: BioMérieux, Charles River, Lonza, NCIMB Ltd & Roche

For media enquiries please contact Kyra Williams on +44 20 7827 6012 or email kwilliams@smi-online.co.uk

For sponsorship opportunities contact Alia Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk

For delegate and group bookings contact Kieran Ronaldson on +44 (0) 20 7827 6744 or email: kronaldson@smi-online.co.uk

7th annual Pharmaceutical Microbiology
22nd – 23rd January 2018
Holiday Inn Kensington Forum, London UK
Organisers: SMi Group
Email: kwilliams@smi-online.co.uk
Tel: +44 (0) 207 827 6012
www.pharma-microbiology.com/EIN

Kyra Williams
SMi Group Ltd
+44 (0)20 7827 6012
email us here


Source: EIN Presswire

Spine Surgery 2017 Global Market Expected to Grow at CAGR of 5.49% and Forecast to 2021

Wiseguyreports.Com Publish New Market Research Report On-“Spine Surgery 2017 Global Market Expected to Grow at CAGR of 5.49% and Forecast to 2021”.

PUNE, INDIA, September 21, 2017 /EINPresswire.com/ —

Spine Surgery Market 2017

Spine surgery helps to restore functions of the spine from spinal disorders that include spine deformities, disc herniation, spondylolisthesis, scoliosis, degenerative discs, trauma, spinal stenosis, and tumors in spine region. Traditional open surgeries and minimally invasive surgeries are helpful for the treatment of spinal disorders. These surgeries involve the usage of various devices and supporting tools for the spine as treatment. The devices used for corrective spine surgery are made of metals such as stainless steel, bioabsorbable materials, polymers, titanium and its alloys, and biomaterials, and are designed in different sizes and shapes for all age groups, and as per end-user requirements.

The analysts forecast the global spine surgery market to grow at a CAGR of 5.49% during 2014-2019.

Covered in this report
This report covers the present scenario and the growth prospects of the global spine surgery market for 2015-2019. To calculate the market size, we consider the revenue generated from the sales of spine surgery devices and biomaterials.

Request a Sample Report @ https://www.wiseguyreports.com/sample-request/211647-global-spine-surgery-market-2015-2019

The report, Global Spine Surgery Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report also covers the vendor landscape and a corresponding detailed analysis of the top five vendors in the market. Also, it discusses the major drivers, challenges, and trends in the market.

Key regions
• Americas
• APAC
• EMEA

Key vendors
• DePuy Synthes
• Medtronic
• NuVasive
• Stryker
• Zimmer

Other prominent vendors
• Aesculap Implant Systems
• Alphatec Spine
• Amedica
• AOI Medical
• Biomet
• Bonesupport
• Cook Medical
• Crosstrees Medical
• DFine
• Exactech
• Globus Medical
• Integra Lifesciences
• Joimax
• K2M
• LDR
• NuTech Medical
• Orthofix International
• Orthovita
• Paradigm Spine
• RTI Surgical
• Smith & Nephew
• Trans1
• Vexim
• VTI
• Zavation

Key questions answered in this report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Any Query, Submit Here @ https://www.wiseguyreports.com/enquiry/211647-global-spine-surgery-market-2015-2019

Table of Contents –Analysis of Key Points

PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Importance of MI techniques in spine surgery
Classification of MIS according to different surgical indications
Trends in MI spine surgery
PART 06: Reimbursement trends in spine surgery
PART 07: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 08: Market segmentation by method
Spinal fusion
Spinal non-fusion
Global spinal fusion surgery market
Global spinal non-fusion surgery market
PART 09: Market segmentation by product
Global spinal implants and instrumentation market
Global spinal biomaterials market
PART 10: Market segmentation by procedure
Global traditional spine surgery market
Global MI spine surgery market
PART 11: Market segmentation by application
PART 12: Geographical segmentation
Spine surgery market in Americas
Spine surgery market in APAC
Spine surgery market in EMEA
PART 13: Market drivers
Growing incidence of spinal disorders
Growing popularity of MI spinal surgery
Increasing elderly population
PART 14: Impact of drivers
PART 15: Market challenges
Complications associated with spinal surgery
Stringent reimbursement policies
Intense competition among vendors
PART 16: Impact of drivers and challenges
PART 17: Market trends
..…..Continued

Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=211647

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

UK Health & Beauty Market Analysis 2017 (By Segment, Key Players and Applications) and Forecasts To 2022

UK Health & Beauty Market 2017 – Current and Future Plans

PUNE, INDIA, September 21, 2017 /EINPresswire.com/ — Pune, India, 21st September 2017: WiseGuyReports announced addition of new report, titled “The UK Health & Beauty Market 2017-2022”.

Summary
"The UK Health & Beauty Market 2017-2022", report offers comprehensive insight and analysis of the market and categories (including forecasts up to 2022), the major players, the main trends, and consumer attitudes. It provides in-depth analysis of the following: the hot issues impacting the market (beauty innovations, latest ingredients, online pureplays and pharmacy funding cuts), strategies for success, market and category sizes and forecasts, retailer profiles, retailer market shares, consumer data and future outlook.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2320996-the-uk-health-beauty-market-2017-2022

The health & beauty market is forecast to grow by 21.1% over the next five years, in part driven by inflation which is set to reach 2.1% in 2017 – the highest level since 2000. While some shoppers will rein in self treating and gifting purchases, the essential nature of the sector protects spend from being diverted elsewhere. Boots is forecast to remain as the market leader in 2017, though its share continues to drop owing to further price pressure from general merchandisers and discounters as well as store environment upgrades at the department stores.

Scope
– Stores remain the primary purchase channel, with 93.5% of sector shoppers buying instore. However, spend continues to shift online, with sales forecast to grow 65.9% out to 2022, to reach 11.6% of the market.
– Skincare is forecast to be the fastest growing subsector out to 2022, with much of this due to product innovation in both the mass and premium markets. We expect skin preparation products such as masks, serums and primers to outperform.
– The health & beauty market remains very female dominated, with 78.0% of females buying into the category in the past year, compared to 41.5% of males. Retailers need to better exploit males’ interest in health, wellness and fitness by encouraging them to buy into other categories such as skincare.

Reasons to buy
– Identify the retailers which are best placed to take advantage of ingredient and beauty innovation trends for 2017/18 to understand the competition in the market and inform new product development.
– Understand what The Body Shop needs to do to build its market share and regain relevance under its new owner, Natura Cosméticos, and what this means for other established retailers in the market.
– Recognise the impact of the online pureplays such as feelunique, Cult Beauty, Lookfantastic as well as ASOS and Amazon in the health & beauty market to adapt your online strategy, and understand how to compete against these retailers.
– Understand the impact of community pharmacy funding cuts on pharmacy retailing and how it will benefit retailers, particularly leaders, in the health & beauty market.
– Identify the drivers in the market such as the health & wellness trend and continued rise of bloggers, celebrities and fitness personalities which are broadening the appeal of health products, and understand which categories are performing well to aid range planning.

Table of Content: Key Points
The hot issues
What people buy
Where people shop
How people shop
Why people shop
Methodology
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/2320996-the-uk-health-beauty-market-2017-2022

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Foam Glass Market Analysis 2017 (By Segment, Key Players and Applications) and Forecasts To 2022

Global Foam Glass Market Research Report 2017 Analysis and Forecast to 2022

PUNE, INDIA, September 21, 2017 /EINPresswire.com/ — Pune, India, 21st September 2017: WiseGuyReports announced addition of new report, titled “Global Foam Glass Sales Market Report 2017”.

In this report, the global Foam Glass market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate of Foam Glass for these regions, from 2012 to 2022 (forecast), covering
United States
China
Europe
Japan
Southeast Asia
India

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/889745-global-foam-glass-sales-market-report-2017

Global Foam Glass market competition by top manufacturers/players, with Foam Glass sales volume, Price (USD/MT), revenue (Million USD) and market share for each manufacturer/player; the top players including
Pittsburgh Corning
GLAPOR
Earthstone
JSC Gomelglass
REFAGLASS
Zhejiang DEHO
YaHong
Huichang New Material
ZhenShen
Zhong Tai Tian Cheng
Zhengdi
ShouBang
Xin Shun Da
YongLi
Aotai
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Black (Gray) foam glass
White foam glass
Others (Multicolor)
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Foam Glass for each application, including
Cryogenic Systems
Heat Transfer Fluid Systems
Chemical Processing Systems
Commercial Piping And Building
Others

Table of Content: Key Points

Global Foam Glass Sales Market Report 2017
1 Foam Glass Market Overview
1.1 Product Overview and Scope of Foam Glass
1.2 Classification of Foam Glass by Product Category
1.2.1 Global Foam Glass Market Size (Sales) Comparison by Type (2012-2022)
1.2.2 Global Foam Glass Market Size (Sales) Market Share by Type (Product Category) in 2016
1.2.3 Black (Gray) foam glass
1.2.4 White foam glass
1.2.5 Others (Multicolor)
1.3 Global Foam Glass Market by Application/End Users
1.3.1 Global Foam Glass Sales (Volume) and Market Share Comparison by Application (2012-2022)
1.3.2 Cryogenic Systems
1.3.3 Heat Transfer Fluid Systems
1.3.4 Chemical Processing Systems
1.3.5 Commercial Piping And Building
1.3.6 Others
1.4 Global Foam Glass Market by Region
1.4.1 Global Foam Glass Market Size (Value) Comparison by Region (2012-2022)
1.4.2 United States Foam Glass Status and Prospect (2012-2022)
1.4.3 China Foam Glass Status and Prospect (2012-2022)
1.4.4 Europe Foam Glass Status and Prospect (2012-2022)
1.4.5 Japan Foam Glass Status and Prospect (2012-2022)
1.4.6 Southeast Asia Foam Glass Status and Prospect (2012-2022)
1.4.7 India Foam Glass Status and Prospect (2012-2022)
1.5 Global Market Size (Value and Volume) of Foam Glass (2012-2022)
1.5.1 Global Foam Glass Sales and Growth Rate (2012-2022)
1.5.2 Global Foam Glass Revenue and Growth Rate (2012-2022)

2 Global Foam Glass Competition by Players/Suppliers, Type and Application
2.1 Global Foam Glass Market Competition by Players/Suppliers
2.1.1 Global Foam Glass Sales and Market Share of Key Players/Suppliers (2012-2017)
2.1.2 Global Foam Glass Revenue and Share by Players/Suppliers (2012-2017)
2.2 Global Foam Glass (Volume and Value) by Type
2.2.1 Global Foam Glass Sales and Market Share by Type (2012-2017)
2.2.2 Global Foam Glass Revenue and Market Share by Type (2012-2017)
2.3 Global Foam Glass (Volume and Value) by Region
2.3.1 Global Foam Glass Sales and Market Share by Region (2012-2017)
2.3.2 Global Foam Glass Revenue and Market Share by Region (2012-2017)
2.4 Global Foam Glass (Volume) by Application

3 United States Foam Glass (Volume, Value and Sales Price)
3.1 United States Foam Glass Sales and Value (2012-2017)
3.1.1 United States Foam Glass Sales and Growth Rate (2012-2017)
3.1.2 United States Foam Glass Revenue and Growth Rate (2012-2017)
3.1.3 United States Foam Glass Sales Price Trend (2012-2017)
3.2 United States Foam Glass Sales Volume and Market Share by Players
3.3 United States Foam Glass Sales Volume and Market Share by Type
3.4 United States Foam Glass Sales Volume and Market Share by Application

4 China Foam Glass (Volume, Value and Sales Price)
..
10 Foam Glass Maufacturing Cost Analysis
10.1 Foam Glass Key Raw Materials Analysis
10.1.1 Key Raw Materials
10.1.2 Price Trend of Key Raw Materials
10.1.3 Key Suppliers of Raw Materials
10.1.4 Market Concentration Rate of Raw Materials
10.2 Proportion of Manufacturing Cost Structure
10.2.1 Raw Materials
10.2.2 Labor Cost
10.2.3 Manufacturing Process Analysis of Foam Glass
10.3 Manufacturing Process Analysis of Foam Glass

11 Industrial Chain, Sourcing Strategy and Downstream Buyers
11.1 Foam Glass Industrial Chain Analysis
11.2 Upstream Raw Materials Sourcing
11.3 Raw Materials Sources of Foam Glass Major Manufacturers in 2016
11.4 Downstream Buyers

12 Marketing Strategy Analysis, Distributors/Traders
12.1 Marketing Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.1.3 Marketing Channel Development Trend
12.2 Market Positioning
12.2.1 Pricing Strategy
12.2.2 Brand Strategy
12.2.3 Target Client
12.3 Distributors/Traders List

13 Market Effect Factors Analysis
13.1 Technology Progress/Risk
13.1.1 Substitutes Threat
13.1.2 Technology Progress in Related Industry
13.2 Consumer Needs/Customer Preference Change
13.3 Economic/Political Environmental Change

14 Global Foam Glass Market Forecast (2017-2022)
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/889745-global-foam-glass-sales-market-report-2017

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Regenerative Fuel Cell(RFC) 2017 Industry Research, Review, Growth, Segmentation, Key Players Analysis and Forecast 2022

This report covers market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies

PUNE, INDIA, September 21, 2017 /EINPresswire.com/ — This report studies Regenerative Fuel Cell (RFC) in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022.

This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering

Access Complete Report @ https://www.wiseguyreports.com/reports/1170333-global-regenerative-fuel-cell-rfc-market-professional-survey-report-2017

Dupont Fuel Cell
Hitachi Ltd
Bloom Energy
Ballard Power
GS Yuasa
Johnson Controls
Delphi
Cmr Fuel Cells
Panasonic Corp
Samsung SDI
SFC Power
Polyfuel
Sharp Corp
Toshiba Corp
Ultracell Corp
Fujikura

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Hydrogen Oxygen Fuel
Alcohol Fuel
Other

By Application, the market can be split into
Commercial
Industrial
Other

By Regions, this report covers (we can add the regions/countries as you want)
North America
China
Europe
Southeast Asia
Japan
India

Request a Sample Report @ https://www.wiseguyreports.com/sample-request/1170333-global-regenerative-fuel-cell-rfc-market-professional-survey-report-2017

If you have any special requirements, please let us know and we will offer you the report as you want.

Table of Contents

Global Regenerative Fuel Cell (RFC) Market Professional Survey Report 2017
1 Industry Overview of Regenerative Fuel Cell (RFC)
1.1 Definition and Specifications of Regenerative Fuel Cell (RFC)
1.1.1 Definition of Regenerative Fuel Cell (RFC)
1.1.2 Specifications of Regenerative Fuel Cell (RFC)
1.2 Classification of Regenerative Fuel Cell (RFC)
1.2.1 Hydrogen Oxygen Fuel
1.2.2 Alcohol Fuel
1.2.3 Other
1.3 Applications of Regenerative Fuel Cell (RFC)
1.3.1 Commercial
1.3.2 Industrial
1.3.3 Other
1.4 Market Segment by Regions
1.4.1 North America
1.4.2 China
1.4.3 Europe
1.4.4 Southeast Asia
1.4.5 Japan
1.4.6 India

2 Manufacturing Cost Structure Analysis of Regenerative Fuel Cell (RFC)
2.1 Raw Material and Suppliers
2.2 Manufacturing Cost Structure Analysis of Regenerative Fuel Cell (RFC)
2.3 Manufacturing Process Analysis of Regenerative Fuel Cell (RFC)
2.4 Industry Chain Structure of Regenerative Fuel Cell (RFC)

3 Technical Data and Manufacturing Plants Analysis of Regenerative Fuel Cell (RFC)
3.1 Capacity and Commercial Production Date of Global Regenerative Fuel Cell (RFC) Major Manufacturers in 2016
3.2 Manufacturing Plants Distribution of Global Regenerative Fuel Cell (RFC) Major Manufacturers in 2016
3.3 R&D Status and Technology Source of Global Regenerative Fuel Cell (RFC) Major Manufacturers in 2016
3.4 Raw Materials Sources Analysis of Global Regenerative Fuel Cell (RFC) Major Manufacturers in 2016

4 Global Regenerative Fuel Cell (RFC) Overall Market Overview
4.1 2012-2017E Overall Market Analysis
4.2 Capacity Analysis
4.2.1 2012-2017E Global Regenerative Fuel Cell (RFC) Capacity and Growth Rate Analysis
4.2.2 2016 Regenerative Fuel Cell (RFC) Capacity Analysis (Company Segment)
4.3 Sales Analysis
4.3.1 2012-2017E Global Regenerative Fuel Cell (RFC) Sales and Growth Rate Analysis
4.3.2 2016 Regenerative Fuel Cell (RFC) Sales Analysis (Company Segment)
4.4 Sales Price Analysis
4.4.1 2012-2017E Global Regenerative Fuel Cell (RFC) Sales Price
4.4.2 2016 Regenerative Fuel Cell (RFC) Sales Price Analysis (Company Segment)

5 Regenerative Fuel Cell (RFC) Regional Market Analysis
5.1 North America Regenerative Fuel Cell (RFC) Market Analysis
5.1.1 North America Regenerative Fuel Cell (RFC) Market Overview
5.1.2 North America 2012-2017E Regenerative Fuel Cell (RFC) Local Supply, Import, Export, Local Consumption Analysis
5.1.3 North America 2012-2017E Regenerative Fuel Cell (RFC) Sales Price Analysis
5.1.4 North America 2016 Regenerative Fuel Cell (RFC) Market Share Analysis
5.2 China Regenerative Fuel Cell (RFC) Market Analysis
5.2.1 China Regenerative Fuel Cell (RFC) Market Overview
5.2.2 China 2012-2017E Regenerative Fuel Cell (RFC) Local Supply, Import, Export, Local Consumption Analysis
5.2.3 China 2012-2017E Regenerative Fuel Cell (RFC) Sales Price Analysis
5.2.4 China 2016 Regenerative Fuel Cell (RFC) Market Share Analysis
5.3 Europe Regenerative Fuel Cell (RFC) Market Analysis
5.3.1 Europe Regenerative Fuel Cell (RFC) Market Overview
5.3.2 Europe 2012-2017E Regenerative Fuel Cell (RFC) Local Supply, Import, Export, Local Consumption Analysis
5.3.3 Europe 2012-2017E Regenerative Fuel Cell (RFC) Sales Price Analysis
5.3.4 Europe 2016 Regenerative Fuel Cell (RFC) Market Share Analysis
5.4 Southeast Asia Regenerative Fuel Cell (RFC) Market Analysis
5.4.1 Southeast Asia Regenerative Fuel Cell (RFC) Market Overview
5.4.2 Southeast Asia 2012-2017E Regenerative Fuel Cell (RFC) Local Supply, Import, Export, Local Consumption Analysis
5.4.3 Southeast Asia 2012-2017E Regenerative Fuel Cell (RFC) Sales Price Analysis
5.4.4 Southeast Asia 2016 Regenerative Fuel Cell (RFC) Market Share Analysis
5.5 Japan Regenerative Fuel Cell (RFC) Market Analysis
5.5.1 Japan Regenerative Fuel Cell (RFC) Market Overview
5.5.2 Japan 2012-2017E Regenerative Fuel Cell (RFC) Local Supply, Import, Export, Local Consumption Analysis
5.5.3 Japan 2012-2017E Regenerative Fuel Cell (RFC) Sales Price Analysis
5.5.4 Japan 2016 Regenerative Fuel Cell (RFC) Market Share Analysis
5.6 India Regenerative Fuel Cell (RFC) Market Analysis
5.6.1 India Regenerative Fuel Cell (RFC) Market Overview
5.6.2 India 2012-2017E Regenerative Fuel Cell (RFC) Local Supply, Import, Export, Local Consumption Analysis
5.6.3 India 2012-2017E Regenerative Fuel Cell (RFC) Sales Price Analysis
5.6.4 India 2016 Regenerative Fuel Cell (RFC) Market Share Analysis

……Continued

Purchase Report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1170333

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Global Endotoxemia Drugs and Companies Pipeline Review H2 2017

Endotoxemia Therapeutic and Drug Pipeline Review H2

PUNE, INDIA, September 21, 2017 /EINPresswire.com/ — Pune, India, 21th September 2017: WiseGuyReports announced addition of new report, titled “Endotoxemia Global Clinical Trials Review, H2, 2017”.

Summary
“Endotoxemia Global Clinical Trials Review, H2, 2017" provides an overview of Endotoxemia clinical trials scenario. This report provides top line data relating to the clinical trials on Endotoxemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2260424-endotoxemia-global-clinical-trials-review-h2-2017

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope
– The report provides a snapshot of the global clinical trials landscape
– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
– The Report provides enrollment trends for the past five years
– Report provides latest news for the past three months

Reasons to buy
– Assists in formulating key business strategies with regards to investment
– Helps in identifying prominent locations for conducting clinical trials which saves time and cost
– Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
– Supports understanding of trials count and enrollment trends by country in global therapeutics market
– Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
– Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Content: Key Points
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Clinical Trials by G7 Countries: Proportion of Endotoxemia to Infectious Disease Clinical Trials 13
Clinical Trials by Phase in G7 Countries 14
Clinical Trials by E7 Countries: Proportion of Endotoxemia to Infectious Disease Clinical Trials 15
Clinical Trials by Phase in E7 Countries 16
Clinical Trials by Phase 17
In Progress Trials by Phase 18
Clinical Trials by Trial Status 19
Clinical Trials by End Point Status 20
Subjects Recruited Over a Period of Time 21
Clinical Trials by Sponsor Type 22
Prominent Sponsors 23
Top Companies Participating in Endotoxemia Therapeutics Clinical Trials 25
Prominent Drugs 27
Clinical Trial Profile Snapshots 28
Appendix 52
Abbreviations 52
Definitions 52
Research Methodology 53
Secondary Research 53
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/2260424-endotoxemia-global-clinical-trials-review-h2-2017

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

New Innovative Laser Technology for Stretch Mark Treatment

Professor Jean-Paul Meningaud, MD, PhD, FEBOMS, Maxillofacial Surgeon, Head of the Department of Plastic, Reconstructive and Aesthetic Surgery at the Henri Mondor Hospital, Paris

Promising results on stretch mark treatment announced at the 38th National Congress of Aesthetic Medicine and Dermatological Surgery in Paris, France

LONDON, UNITED KINGDOM, September 21, 2017 /EINPresswire.com/ — Professor Jean-Paul Meningaud (1) presented his research into the possibilities of RecoSMA® (LINLINE) in stretch mark treatment. This unique & revolutionary new method to repair damaged human tissue has been developed and patented by LINLINE, and is implemented in the MULTILINE™ series of devices. The 38th National Congress of Aesthetic Medicine and Dermatological Surgery, was held 8th and 9th September 2017 at the Palais des Congrès, Paris, by the French Society of Aesthetic Medicine. http://www.sfme.info/sfme

The French Society of Aesthetic Medicine was founded in 1973, and celebrates its 44th anniversary this year. It brings together physicians, experts and non-experts who, in their daily practice, offer their patients advice, care or treatments to improve their aesthetic appearance. The French Society of Aesthetic Medicine organises every year it’s National Congress which attracts more than 1,000 participants. It publishes the "Journal of Aesthetic Medicine and Dermatological Surgery" every three months.

The objective of this study was to assess the efficacy of RecoSMA® technology for Striae Distensae (SD). The study investigated the stimulation of fibroblasts and the improvement of the quality of the skin in the area affected by SD and to study the response of the organism to these micro traumas in cell regeneration leading to newly formed collagen and elastin fibres. The prospective research project was conducted by the Department of Plastic, Reconstructive and Aesthetic Surgery at the Henri Mondor Hospital, Paris.

Method: A total of 20 patients with various stages of SD were included. Pregnant or breast feeding patients and patients who had previous treatment for SD were excluded. Treatment was undertaken using an Er:YAG laser 2936nm with RecoSMA ® technology (LINLINE). Each patient received a total of 6 sessions with four week intervals. During treatment no anaesthetic was required or needed. Follow ups were 3 and 6 months.

Results: The results were analysed by examining the photographs and ultrasound images of the areas treated.

• 10% Patients experienced very good improvement
• 60% Patients showed good improvement
• 20% moderate improvement
• 10% slight improvement

Conclusion: After 3 months the study revealed 70% of patients had a good or very good improvement of SD.

• The RecoSMA® laser vastly improves the elasticity and firmness of the skin
• Improves significantly scar quality
• Is effective in treating SD with no side effects
• Has very promising preliminary results

RecoSMA ® is a unique technology, recently invented by LINLINE, to treat different tissue conditions such as aged skin, scarring, age-related hyperpigmentation, non-healing wounds, psoriasis etc. It is based on a sophisticated laser optical system, converting the main laser beam into 10,000 microbeams per square cm, which simultaneously interact with the tissue. The powerful mechanical waves from every micro beam scatter from the surface to the deeper layers, creating what has never existed before; non-thermal partial damage of human cells up to 6 mm in depth. This new technology is incomparable to any other – including light or ultrasound based methods. This is due to the great response of the tissue treated, leading to its total regeneration, its functional restoration, and the promotion of fast neovascularisation, becoming truly younger and healthier. The evidence of the effectiveness of the new RecoSMA® technology is backed up by numerous pre-clinical and clinical studies for aged skin rejuvenation and lifting, correction of scars, treating trophic ulcers and many other applications.

(1) Professor Jean-Paul Meningaud, MD, PhD, FEBOMS, Maxillofacial Surgeon, Head of the Department of Plastic, Reconstructive and Aesthetic Surgery at the Henri Mondor Hospital, Paris. A Fellow of the European Board of Oro-Maxillofacial Surgery, he graduated in microsurgery and holds the HDR (postdoctoral degree authorising the holder to direct the research of others). He received the James Barret Brown award in 2011. In 2014 he was elected to be President of the EACMFS (European Association for Cranio Maxillo Facial Surgery) for 2018-2020. He is in charge of diplomas in cosmetic medicine and runs research into regenerative medicine and aesthetic surgery.

SOURCE: LINLINE Medical Systems SAS

RecoSMA® – Time Back Trigger – #RecoSMA

LINLINE Medical Systems

Founded in 1994 as a research company, LINLINE (http://www.linline.com) is an international manufacturer of high quality medical laser devices for aesthetic, dermatological and surgical purposes.

Richie Hunt
LINLINE Medical Systems
0044 774 732 6762
email us here

RecoSMA ®: 16 years later and back on the beach!


Source: EIN Presswire